What is the Life Expectancy for Charcot-Marie-Tooth 1A?
At a Glance
Charcot-Marie-Tooth disease type 1A (CMT1A) does not shorten lifespan, and people with this condition generally have a normal life expectancy. It is a slowly progressive neuropathy that affects peripheral nerves, but rarely impacts internal organs or breathing muscles.
Receiving a genetic diagnosis like Charcot-Marie-Tooth disease type 1A (CMT1A) can be frightening, particularly when considering your future and your family. However, it is important to know that CMT1A is not considered a fatal condition and does not typically shorten your lifespan. People living with CMT1A generally have a normal life expectancy [1][2].
How CMT1A Progresses Over Time
CMT1A is a chronic peripheral neuropathy, meaning it is a long-term condition that affects the nerves located outside the brain and spinal cord [2][3]. Because it is a hereditary (genetic) condition, you may wish to speak with a genetic counselor to understand inheritance patterns and how it might affect your children or other relatives.
The disease is known for progressing very slowly over decades [2][1]. Over time, you may notice gradual changes in mobility, physical function, and sensation. CMT1A impacts both the motor nerves (which control movement) and sensory nerves (which process feeling) in your feet, legs, hands, and arms [1][4].
Motor Changes and Mobility:
Muscle weakness often begins in the lower legs and feet. This specifically affects the ankle dorsiflexors—the muscles that lift the front part of your foot—which can lead to a condition called “foot drop” or changes in your gait [5][6]. As the condition progresses, many people develop characteristic foot changes such as high arches (pes cavus) and curled toes (hammertoes) [7][8].
A common and understandable fear is whether you will eventually require a wheelchair. While everyone’s progression is different, the vast majority of people with CMT1A remain ambulatory (able to walk) throughout their lives, often with the help of walking aids or supportive gear [9][10].
Sensory Changes and Hand Function:
In addition to muscle weakness, many people experience sensory loss, such as numbness, tingling, or varying degrees of nerve pain (neuropathic pain) in their hands and feet [11]. Over time, muscle loss or weakness can also extend into the hands, making fine motor tasks like buttoning clothes or opening jars more difficult [1].
Does It Affect Internal Organs or Breathing?
One of the most reassuring facts about CMT1A is that it rarely affects internal organs, such as the heart, liver, or kidneys [1]. The core internal systems that sustain life continue to function normally.
Similarly, it is uncommon for CMT1A to impact the muscles used for breathing [1]. Though there have been rare, isolated reports of weakness in the breathing muscles (the diaphragm) leading to respiratory issues, this is not a typical symptom or complication of this specific subtype [12].
Preserving Your Quality of Life
While CMT1A will not cut your life short, managing its slow progression is key to maintaining your independence. Proactive treatments focus on symptom management and supporting your body:
- Physical Therapy: Custom exercises can help preserve muscle strength, improve balance, and reduce joint pain [13][14].
- Occupational Therapy: An occupational therapist can teach you adaptive techniques and provide tools to manage hand weakness, helping you maintain independence in daily tasks.
- Orthotic Devices: Supportive gear, such as ankle-foot orthoses (AFOs) or custom orthopedic shoes, can stabilize your gait and make walking safer and less tiring [13][14].
- Pain Management: If you experience nerve pain or uncomfortable tingling, your care team can recommend specific medications or therapies to manage these sensory symptoms [11].
- Weight Management: Maintaining a healthy weight is highly beneficial, as it reduces the mechanical burden on weakened leg muscles and joints.
- Surgical Options: In some cases, orthopedic foot surgery may be an option to correct severe high arches or hammertoes if orthotics are no longer effective [7].
By working closely with a care team that includes neurologists, physical therapists, occupational therapists, and orthotists, you can effectively manage the physical changes of CMT1A and lead a full, active life.
Common questions in this guide
Does CMT1A affect your lifespan?
Will I end up in a wheelchair if I have CMT1A?
How does CMT1A progress over time?
Does CMT1A affect breathing or internal organs?
When should I get ankle-foot orthoses (AFOs) for CMT1A?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Should I see a genetic counselor to better understand the inheritance patterns of CMT1A and how it might affect my children or other family members?
- 2.When is the appropriate time to get fitted for ankle-foot orthoses (AFOs) or custom orthotics, and how will I know I need them?
- 3.Could occupational therapy help me maintain hand strength and dexterity for daily tasks like buttoning shirts or using utensils?
- 4.What are my options for managing the nerve pain, numbness, or tingling I am experiencing in my feet and hands?
- 5.At what point should I consult with an orthopedic surgeon regarding the structural changes, like high arches or hammertoes, in my feet?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies.
Klein CJ
Continuum (Minneapolis, Minn.) 2020; (26(5)):1224-1256 doi:10.1212/CON.0000000000000927.
PMID: 33003000 - 2
Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease.
Millere E, Rots D, Simrén J, et al.
European journal of neurology 2021; (28(3)):974-981 doi:10.1111/ene.14689.
PMID: 33340200 - 3
New developments in Charcot-Marie-Tooth neuropathy and related diseases.
Pareyson D, Saveri P, Pisciotta C
Current opinion in neurology 2017; (30(5)):471-480 doi:10.1097/WCO.0000000000000474.
PMID: 28678038 - 4
Paternal gender specificity and mild phenotypes in Charcot-Marie-Tooth type 1A patients with de novo 17p12 rearrangements.
Lee AJ, Nam DE, Choi YJ, et al.
Molecular genetics & genomic medicine 2020; (8(9)):e1380 doi:10.1002/mgg3.1380.
PMID: 32648354 - 5
Postural instability in Charcot-Marie-Tooth 1A disease.
Tozza S, Aceto MG, Pisciotta C, et al.
Gait & posture 2016; (49()):353-357 doi:10.1016/j.gaitpost.2016.07.183.
PMID: 27491052 - 6
Walking Speed Is Correlated With the Isokinetic Muscular Strength of the Knee in Patients With Charcot-Marie-Tooth Type 1A.
Reynaud V, Morel C, Givron P, et al.
American journal of physical medicine & rehabilitation 2019; (98(5)):422-425 doi:10.1097/PHM.0000000000001084.
PMID: 30365400 - 7
Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot-Marie-Tooth's Disease in Brazil.
Machado RIL, Souza PVS, Farias IB, et al.
Journal of pediatric genetics 2023; (12(4)):301-307 doi:10.1055/s-0042-1747934.
PMID: 38162165 - 8
Spinal and bulbar muscular atrophy and Charcot-Marie-Tooth type 1A: Co-existence of two rare neuromuscular genetic diseases in the same patient.
Sagnelli A, Scaioli V, Piscosquito G, et al.
Neuromuscular disorders : NMD 2015; (25(10)):800-1.
PMID: 26298608 - 9
Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study.
Thomas FP, Saporta MA, Attarian S, et al.
Journal of clinical neuromuscular disease 2022; (24(1)):7-17 doi:10.1097/CND.0000000000000426.
PMID: 36005469 - 10
Gait Pattern in Charcot-Marie-Tooth Disease Type 1A According to Disease Severity.
Park J, Joo SY, Choi BO, et al.
Journal of personalized medicine 2023; (13(10)) doi:10.3390/jpm13101473.
PMID: 37888085 - 11
Neuropathic pain in Charcot-Marie-Tooth disease: A clinical and laser-evoked potential study.
Peretti A, Squintani G, Taioli F, et al.
European journal of pain (London, England) 2022; (26(4)):929-936 doi:10.1002/ejp.1922.
PMID: 35129250 - 12
Fontan Failure Secondary to Charcot-Marie-Tooth-Induced Phrenic Neuropathy.
Abdul TY, Schneider AE, Cetta F, Driscoll DJ
Texas Heart Institute journal 2018; (45(4)):270-272 doi:10.14503/THIJ-17-6337.
PMID: 30374244 - 13
Orthopaedic shoes along with physical therapy was effective in Charcot-Marie-Tooth patient over 10 years.
Bensoussan L, Jouvion A, Kerzoncuf M, et al.
Prosthetics and orthotics international 2016; (40(5)):636-42 doi:10.1177/0309364615584657.
PMID: 26015326 - 14
Changes in walking velocity and stride parameters with age in children with Charcot-Marie-Tooth disease.
Õunpuu S, Pierz KA, Acsadi G, Wren TAL
Neuromuscular disorders : NMD 2020; (30(10)):825-832 doi:10.1016/j.nmd.2020.08.359.
PMID: 32928646
This information about CMT1A life expectancy and disease progression is for educational purposes only. Always consult your neurologist or healthcare provider for medical advice regarding your specific condition and symptom management.
Get notified when new evidence is published on Charcot-Marie-Tooth disease type 1A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.